Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling

Tyrosine kinase inhibitors (TKIs) induce molecular remission in the majority of patients with chronic myelogenous leukemia (CML), but the persistence of CML stem cells hinders cure and necessitates indefinite TKI therapy. We report that CML stem cells upregulate the expression of pleiotrophin (PTN)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Himburg, Heather A., Roos, Martina, Fang, Tiancheng, Zhang, Yurun, Termini, Christina M., Schlussel, Lauren, Kim, Mindy, Pang, Amara, Kan, Jenny, Zhao, Liman, Suh, Hyung, Sasine, Joshua P., Sapparapu, Gopal, Bowers, Peter M., Schiller, Gary, Chute, John P.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2019
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6934217/
https://ncbi.nlm.nih.gov/pubmed/31613796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129061
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items